

Transcriptional profiles in HIV reservoirs- new insights using HIV-seq

Sushama Telwatte, PhD

Locarnini Fellow in Virology, The Peter Doherty Institute
for Infection and Immunity

Session: Discovery and Translational Science:
Reservoir

Disclosure of interest: None




Acknowledgment

With gratitude to people living with HIV, past and present, whose contributions make this research possible



Challenges in studying the HIV reservoir

- There is currently no cure for HIV
- Despite therapy, HIV-1 persists in latently-infected CD4+ T cells
- Majority of proviruses are defective, however reservoir cells can be *transcriptionally active*
 - **low-level antigen production^{1,2}**
 - **immune activation and dysfunction³**
 - **potential reseeding of replication-competent virus(?)^{4,5}**
- Mechanisms underlying the persistence of HIV remain unclear




What are the blocks to HIV transcription during ART?

Which cellular factors are involved?


Understanding blocks to HIV-1 transcription



Prof. Steven Yukl,
M.D. (UCSF)



Assay Targets



HIV-1 transcription in the blood and gut-challenges for single cell analyses


Infected cells from people living with HIV (PWH) exhibit successive blocks to HIV transcription

Blocks to transcription → inability to complete viral life cycle

Found that only a small proportion of HIV transcripts are polyadenylated

scRNAseq relies on priming at the poly(A) tail

Need for new targeted capture approaches to sensitively identify transcriptionally active reservoir cells



How can we study rare HIV-infected cells under ART?


Development of HIV-seq




Prof. Steven
Yukl, M.D.
(UCSF/VAMC)

Prof. Nadia
Roan, Ph.D.
(Gladstone
Inst.)

Dr. Julie
Frouard, Ph.D.
(Gladstone
Inst.)



Study design and cells analysed



Cohorts: TreatAcute and SCOPE (San Francisco, USA)

Total Cells	HIV RNA+ cells	HIV RNA+ cells (ART suppressed)	Infected cell frequencies	HIV transcript levels (reads/cell)
85,667	1,072	25*	0.061% - 2.42%	1 – 1063*

**highest # of cells analysed*

HIV_{low}: 1-50 copies
HIV_{high}: 51-200 copies

Pre-ART
viremic
'Week 0'

On ART
suppressed
'Week 24/45'

Pre-ART
viremic
'Week 0'

Differentially expressed proteins at single cell level

Cellular Indexing of Transcriptomes and Epitopes by Sequencing ('CITE-seq'): gene expression

(transcriptome) and **surface protein levels** (epitopes) within the same cell


16 antibody-derived tags (ADTs) for accurately phenotyping CD4+ T cells and gating out CD8+ T cells, B cells, and monocytes

HIV RNA+ cells express lower levels of CD45RA and higher levels of CD45RO vs. HIV RNA- cells

Enrich target cells derived tags

Lower CD4 expression in HIV RNA+ cells during active viremia compared to HIV RNA+ cells during ART suppression

(consistent with Nef-mediated downregulation) **single cell capture**




HIV RNA+ cells exhibit a heterogeneous phenotype but are enriched among Tem cells

HIV RNA+ cells:

- **overrepresented** in T effector memory
- **under-represented** among central memory (Tcm) cells and those of the CCR7+CD27- phenotype

Consistent with prior scRNAseq data^{1,2}

Transitional memory (Ttm), regulatory T cells (Treg), and T follicular helper (Tfh) cells were equally represented among uninfected and HIV RNA+ CD4+ T cells




HIV RNA+ cells during viremia are enriched among cells with a cytotoxic/Th1 phenotype

Louvain clustering identified 13 clusters

Classical CD4+ T cell subsets did not define the clusters

HIV RNA+ cells from viremic PWH were enriched in Cluster 6:

- high expression of cytotoxic and cytolytic genes, including *GZMA*, *GZMB*, *GZMH*, *GZMM*, *PRF1*, *GNLY*, *NKG7*
- Th1-defining factors *IFNG* and *TBX21*
- Cytotoxic Th1 phenotype^{1,2}



Upregulation of both NFAT, PKC, and chemokine signalling pathways in HIV RNA+ cells

Upregulation of the NFAT pathway (*MAF*, *CLTA4*) in HIV RNA+ cells

- consistent with NFAT as a driver of HIV transcription^{1,2}


Upregulation of the PKC pathway

- involved in HIV gene expression and latency reversal^{3,4}


Upregulation of chemokine signaling pathways (*CXCR6*, the *CXCR6* ligand *CXCL13*, and *PLCB1*)

Cellular state conducive to viral replication

E.



Lower restriction factor expression in HIV RNA+ vs. HIV RNA- cells from same individuals



Pre-ART
viremic
'Week 0'

Table 4. Differentially expressed genes between HIV RNA+ cells vs. HIV RNA- cells during viremia (n=4)

Gene	Log FC	FDR
APOBEC3A	-4.074	4.36E-07
SERPINA1	-3.813	1.40E-13
IFITM3	-1.026	1.14E-08

Lower restriction factor expression may be conducive to HIV persistence and likely favors HIV transcription at the single-cell level

*Unable to assess sex-based differences

HIV RNA+ cells under ART suppression show anti-inflammatory signature


HIV-transcribing cells from ART-suppressed timepoints:

Cluster 1 (long lived CD4+ T cells) &
Cluster 3 (Tem MALAT1^{high})

Distinct anti-inflammatory signature:

- elevated TGF- β
- diminished IFN signaling

HIV RNA+ cells during ART suppression do not show a cytotoxic phenotype (as found during viremia)



Summary

HIV RNA+ cells from viremic PWH are heterogeneous but exhibit shared features

- More likely to be effector memory T cells (Tem)
- Display previously undescribed state more conducive to viral replication, with low expression of restriction factors and increased activation of cellular pathways promoting HIV gene expression
- Exhibit a cytotoxic signature characterized by higher expression of granzymes, perforin, and granulysin and a Th1 signature

HIV RNA+ cells from suppressed PWH:

- Preferentially Tem cells but do not exhibit a cytotoxic signature
- TGF- β -associated signature is a phenomenon that only emerges in the context of ART suppression

Key Populations and Impact on Community

Key Population: People living with HIV

Impact: HIV has important differential effects on cells based on whether people are on or off treatment

Understanding these differences is key to designing more targeted and effective cure strategies

Supports the long-term goal of safe, effective, and accessible cure for everyone living with HIV



Acknowledgments



Telwatte lab
Carolin Tumpach
Jesslyn Ong
Rohan Goyal
Jiwen Chen
Farida Darmani

Lewin lab
Sharon Lewin
Michael Roche
Ajantha Rhodes
Youry Kim
Haoming Liu
Paula Ceval
Judy Chang



**Thank you to the study participants,
without whom this work would
not be possible**



NCIRE
The Veterans Health Research Institute



University of California
San Francisco

**UCSF/ San
Francisco VA
Medical Center**

Steven Yukl
Joseph Wong
Sara Morón-López
Holly Martin
Peggy Kim
Tsui-Hua Chen
Nikhila Kadiyala
Adam Wedrychowski

**GLADSTONE
INSTITUTES**

Roan lab
Nadia Roan
Julie Frouard
Xiaoyu Luo

UCSF

Bakar Computational Health
Sciences Institute

Butte lab

Atul Butte
Doug Arneson



Division of HIV,
Infectious Diseases
& Global Medicine
Department of Medicine

Steven Deeks
Peter Hunt
Becky Hoh
SCOPE Team

Sulaggi Lee
Vivian Pae
Sannidhi
Sarvadhababhatla

Funding



**Doherty
Institute**
A joint venture between the University
of Melbourne and Melbourne Health



UNIVERSITY
OF
CALIFORNIA
Office
of the
President



**CALIFORNIA HIV/AIDS
RESEARCH PROGRAM**




Center for AIDS Research
University of California San Francisco
Gladstone Institute of Virology & Immunology



**National Institute of
Diabetes and Digestive
and Kidney Diseases**

Research Seed Funding of the University of California
(Grant Number R00RG3113), UCSF/ GIVI Center for AIDS
Research (Mentored Scientist in HIV Award, CFAR; Grant#
P30 A1027763 award #A120163. California HIV/AIDS
Research Program (Grant number BB19- SF-009, Doherty
Institute for Infection and Immunity Locarnini Fellowship in
Virology and University of Melbourne Department of
Infectious Diseases Research Support Package, Gilead
Australia Fellowship

Antiviral factor expression in CD4+ T cells is higher during viremia than ART-suppression




In agreement with findings in non-paired studies of non-controller, viremic, and ART-suppressed individuals (Abdel-Mohsen et al., Retrovirology. 2013)

Table 2. Paired samples of CD4+ T cells during viremia vs. ART suppression (n=3)

Gene	Log FC	FDR
IFI6	0.618	0
ISG15	0.577	0
IFITM1	0.575	0
MX1	0.525	0
TRIM22	0.309	0
IFITM2	0.306	0
IFITM3	0.260	2.42E-99
BST2	0.256	0


Upregulation of restriction factors during viremia vs. ART-suppression in HIV RNA+ CD4+ T cells



Interferon-stimulated genes, including MX1, IFI27 and ISG15 are all upregulated in HIV RNA+ CD4+ T cells from viremia vs. ART suppression

These ISGs were upregulated during acute infection but also remained chronically elevated during ART suppression (Mackelprang et al., iScience 2023)


Table 3. HIV RNA+ CD4+ T cells in viremia vs. suppression in paired samples



Mackelprang et al., iScience 2023

Figure 2

A.



■ HIV RNA+
■ All CD4+ T cells

